AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34838156
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally
Trial: 32085669
Drug: Trastuzumab-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab-based neoadjuvant therapy
Trial: 32085669
Drug: Trastuzumab-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab-based neoadjuvant therapy with ct-miR-148a and ct-miR-140-5p
Trial: 33135865
Drug: Ertugliflozin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/metformin FDC tablet (2.5/500 mg or 7.5/850 mg)
Trial: 33135865
Drug: Canadian-sourced metformin
RxNorm normalized name: Canadian bluegrass pollen extract
DrugBank: Poa compressa pollen (DB10713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canadian-sourced metformin coadministered with ertugliflozin
Trial: 34149587
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy (CT)
Trial: 36333268
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg once daily) and Savolitinib (300 mg twice daily)
Trial: 34767869
Drug: Deucravacitinib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib (selective TYK2 inhibitor)
Trial: 33887241
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (25 μg)
Trial: 33887241
Drug: Slow-release dinoprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release dinoprostone pessary (10 μg)
Trial: 33476803
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg, intravenous, every 2 weeks for ≤12 months)
Trial: 32731478
Drug: Apple beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple beverage (234 mg flavanols)
Trial: 32731478
Drug: Coffee berry
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee berry beverage (440 mg chlorogenic acid)
Trial: 32731478
Drug: Blueberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry beverage (300 mg anthocyanins)
Trial: 35692065
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone acetate group (n=28)
Trial: 35692065
Drug: Combined with
RxNorm normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined with local injection Triamcinolone acetonide group (n=30)
Trial: 36065092
Drug: ZYIL1 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 (oral NLRP3 inflammasome inhibitor)
Trial: 34220712
Drug: Ding-Kun Pill
RxNorm normalized name: Ding xiang
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ding-Kun Pill (DKP) 7g twice daily
Trial: 34220712
Drug: Placebo 7g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 7g twice daily
Trial: 32216911
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of neurohumoral blocker therapy
Trial: 32216911
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors
Trial: 32216911
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of beta‐blockers
Trial: 32216911
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors and beta‐blockers
Trial: 35751480
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection combined with finasteride and minoxidil
Trial: 35751480
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no botulinum toxin A injection)
Trial: 32531982
Drug: Prebiotic oligofructose-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic oligofructose-enriched inulin (10 g per day)
Trial: 35889769
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination containing phytosterols, bergamot, olive fruits, and vitamin K2
Trial: 36240610
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low fixed dose of GH (0.1 mg/day)
Trial: 36240610
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of GH (initially 0.13 mg/day, increased to 0.31 mg/day)
Trial: 38363950
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (CPT) alone
Trial: 34275488
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of DMARDs
Trial: 33469728
Drug: Intravenous GGS
RxNorm normalized name: Immunoglobulin, anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH fragment) fusion protein with peptide linker (GGS)2 fusion protein with immunoglobulin anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GGS (freeze‐dried sulfonated human normal immunoglobulin)
Trial: 33469728
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (steroid pulse)
Trial: 32400000
Drug: Estrogen Deprivation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole
Trial: 35450742
Drug: mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron 50 mg once daily
Trial: 35450742
Drug: solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 5 mg per day
Trial: 35450742
Drug: combined solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined solifenacin 5 mg and mirabegron 50 mg once daily
Trial: 32872748
Drug: Gout patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gout patients receiving anti-gout medication
Trial: 34739002
Drug: Early metabolic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early metabolic support (EMS) with peripheral amino acid infusions
Trial: 34059363
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication counselling method (CMC)
Trial: 33107439
Drug: Dose Titration
RxNorm normalized name: Rebif Rebidose Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Titration (DT)
Trial: 35793609
Drug: Na2SeO3 (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na2SeO3 (sodium selenite) continuous infusion at a pharmacological dose of 4 mg Se/day on day-1, followed by a high nutritional dose of 1 mg Se/day for 9 days
Trial: 32103326
Drug: Decontamination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decontamination with polymyxin B, tobramycin, vancomycin, and amphotericin B, administered four times per day starting the day before surgery until postoperative day 7.
Trial: 32103326
Drug: Placebo (amphotericin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (amphotericin B only), administered four times per day starting the day before surgery until postoperative day 7.
Trial: 35776749
Drug: Data augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data augmentation approach
Trial: 33129455
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration of toxic K. brevis (> 1 million cells L‐1) at normoxic levels (7.2 mg L‐1)
Trial: 33129455
Drug: Moderate hypoxia
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypoxia (1.5 mg L‐1) with high concentration of K. brevis
Trial: 33129455
Drug: Severe hypoxia
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe hypoxia (0.63 mg L‐1) with high concentration of K. brevis
Trial: 33129455
Drug: Normoxic control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoxic control (7.3 mg L‐1) with no K. brevis
Trial: 33069888
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) with pembrolizumab 200 mg (up to 2 years)
Trial: 33069888
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) without pembrolizumab (chemotherapy alone)
Trial: 34034784
Drug: COVID-19 specific
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 specific monoclonal antibodies (mABs) authorized by the EUAs (bamlanivimab and etesevimab; casirivimab and imdevimab)
Trial: 32162808
Drug: Sequential FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential FOLFIRI followed by Cisplatin and Docetaxel
Trial: 32162808
Drug: Tumor PD-L1
RxNorm normalized name: HUMAN BREAST TUMOR CELL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor PD-L1 ≥ 1% in sequential chemotherapy
Trial: 35627351
Drug: Core strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core strength training (CST) programme (n = 16) performed thrice weekly
Trial: 33057670
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual with adjunctive psycho-social intervention for medication adherence
Trial: 33057670
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual without adjunctive psycho-social intervention
Trial: 32150017
Drug: Single-session treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session treatment group (26 patients)
Trial: 32150017
Drug: Weekly management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly management group (27 patients)
Trial: 35351871
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity counselling intervention (introductory behavioural coaching session followed by eight weekly follow-up sessions)
Trial: 37640025
Drug: treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: 34343108
Drug: Metformin (1000–2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000–2000 mg daily for 3 months)
Trial: 34343108
Drug: Insulin (non-MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (non-MET group)
Trial: 35917806
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 40 IU
Trial: 34861827
Drug: CRAFT written
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRAFT written material as a supplement
Trial: 33831623
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inhaled salbutamol)
Trial: 33824226
Drug: Choir intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choir intervention (2-hr ensemble singing + 1-hr home vocal training weekly)
Trial: 33824226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (listened to a 3-hr playlist weekly, attended concerts, and socialized online)
Trial: 32302064
Drug: Calcium glucoheptonate
RxNorm normalized name: Calcium glucoheptonate
DrugBank: Calcium glucoheptonate (DB00326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium glucoheptonate (250 mg/10 mL, two oral ampoules)
Trial: 32302064
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (500 mg elemental calcium, one effervescent tablet)
Trial: 34326053
Drug: Identification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identification of open bile ducts with administration of 20-40 mL SMOFlipid5% in the bile tract
Trial: 34518246
Drug: Friendship Bench
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friendship Bench (FB) intervention, details on dosage and duration not specified.
Trial: 34518246
Drug: Cluster randomised
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster randomised controlled trial of the optimised Friendship Bench intervention, details on dosage and duration not specified.
Trial: 35062944
Drug: Established non-invasive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established non-invasive ventilation (NIV) treatment
Trial: 34570177
Drug: Levetiracetam, 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam, 125 mg, twice daily for 4 weeks
Trial: 32205751
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of botulinum toxin (8U)
Trial: 32205751
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of botulinum toxin
Trial: 33323473
Drug: Steering immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steering immunosuppressive therapy by levels of virus-specific T cells
Trial: 33323473
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with trough-level monitoring of immunosuppressants
Trial: 34515737
Drug: CONNECT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CONNECT intervention (3 monthly visits with trained oncology nurses)
Trial: 37336058
Drug: IC14 (anti-CD14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (anti-CD14 monoclonal antibody)
Trial: 38431043
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapy
Trial: 34326209
Drug: Nicotinamide mononucleotide
RxNorm normalized name: NICOTINAMIDE MONONUCLEOTIDE
DrugBank: Nicotinamide Mononucleotide (DB03227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide mononucleotide (NMN) therapy
Trial: 35535503
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine (100 µg)
Trial: 34876434
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg ATG
Trial: 38059944
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy (ST)
Trial: 34387740
Drug: N-acetyl-L-leucine (NALL)
RxNorm normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-leucine (NALL) 4 g/day for patients ≥ 13 years, weight-tiered doses for patients 6-12 years
Trial: 34387740
Drug: N-acetyl-L-leucine (NALL)
RxNorm normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-leucine (NALL)
Trial: 35517892
Drug: Melatonin (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (21 mg/day)
Trial: 32297703
Drug: Intrarenal artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells (2.5 × 10^7 cells for each intrarenal artery)
Trial: 32297703
Drug: Standardized pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized pharmacotherapy only (control group)
Trial: 32297703
Drug: Intrarenal artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells
Trial: 36457297
Drug: Crisis Counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisis Counseling (CC)
Trial: 32367870
Drug: 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μg oral misoprostol
Trial: 34559113
Drug: Chuna Manual
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chuna Manual Therapy (CMT) administered once a week for 8 weeks
Trial: 34559113
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug treatment (Control)
Trial: 37723577
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg QD
Trial: 38923871
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg QD
Trial: 34968730
Drug: Dose-escalated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated group (upadacitinib 30 mg QD)
Trial: 39287491
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy
Trial: 35738801
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) treatment for uHCC
Trial: 33829647
Drug: Enoxaparin followed
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin followed by a vitamin K antagonist
Trial: 34042412
Drug: Short-wave diathermy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-wave diathermy (SWD) treatment
Trial: 33104028
Drug: Multi-Component Cognitive
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Component Cognitive Stimulation Therapy (SADEM)
Trial: 32505810
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral xylitol wipes (7 g xylitol)
Trial: 32505810
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene regimen (SOC)
Trial: 36210436
Drug: ED GOAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED GOAL intervention administered by trained nurses
Trial: 35746524
Drug: Autogenous vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous vaccine treatment (M. bovis, M. bovoculi, Mycoplasma bovoculi antigens)
Trial: 35746524
Drug: Commercial M.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial M. bovis vaccine treatment
Trial: 35746524
Drug: Sham vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham vaccine treatment (adjuvant only)
Trial: 35746524
Drug: Autogenous vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous vaccine treatment
Trial: 35746524
Drug: Sham vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham vaccine treatment
Trial: 34263623
Drug: Intraoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative low-dose ketamine (0.2 mg/kg/h)
Trial: 35862873
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg subcutaneously once every 28 days)
Trial: 35862873
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg orally once daily)
Trial: 34822235
Drug: Spiritual intervention
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiritual intervention (5 sessions before chemotherapy)
Trial: 32964833
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of opioids and non-opioid CNSAM
Trial: 32964833
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (no medication use)
Trial: 35460726
Drug: Vebicorvir (VBR)
RxNorm normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vebicorvir (VBR) 300 mg once daily + NrtI
Trial: 32818353
Drug: Intracameral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral moxifloxacin (0.03 mL, 150 μg in 0.03 mL Vigamox solution)